Francesco Gelsomino

IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC”.

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1735

N/A

0.345DataRank · unranked

9 citations

Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo +26 more

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

Annals of Oncology(2024)10.1016/j.annonc.2024.11.014

N/A

0DataRank · unranked

25 citations

Lingzhi Hong, Arielle Elkrief, Rohit Thummalapalli, Alissa J. Cooper, Biagio Ricciuti +43 more